Global Markets Directs, Thymus Cancer - Pipeline Review, H2 2014, provides an overview of the Thymus Cancers therapeutic pipeline.
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/238879
This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/238879
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Thymus Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Thymus Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Thymus Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thymus Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thymus Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction
Global Markets Direct Report Coverage
Thymus Cancer Overview
Therapeutics Development
Pipeline Products for Thymus Cancer - Overview
Pipeline Products for Thymus Cancer - Comparative Analysis
Thymus Cancer - Therapeutics under Development by Companies
Thymus Cancer - Therapeutics under Investigation by Universities/Institutes
Thymus Cancer - Pipeline Products Glance
Clinical Stage Products
Thymus Cancer - Products under Development by Companies
Thymus Cancer - Products under Investigation by Universities/Institutes
Thymus Cancer - Companies Involved in Therapeutics Development
Merck & Co., Inc.
Nerviano Medical Sciences S.r.l.
Novartis AG
Onxeo SA
Sumitomo Dainippon Pharma Co., Ltd.
Thymus Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amrubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 1 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thymus Cancer - Recent Pipeline Updates 43
Thymus Cancer - Product Development Milestones 50
Featured News & Press Releases
Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014
May 14, 2014: Phase II data of Nerviano Medical Sciences kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO
Jul 18, 2013: Belinostat gets European orphan drug designation for the treatment of malignant thymomas
May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Thymus Cancer, H2 2014
Number of Products under Development for Thymus Cancer - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Thymus Cancer - Pipeline by Merck & Co., Inc., H2 2014
Thymus Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2014
Thymus Cancer - Pipeline by Novartis AG, H2 2014
Thymus Cancer - Pipeline by Onxeo SA, H2 2014
Thymus Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Thymus Cancer Therapeutics - Recent Pipeline Updates, H2 2014
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Visit: http://www.prnewswire.com/news/marketresearchreports.biz
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/238879
This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/238879
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Thymus Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Thymus Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Thymus Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thymus Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thymus Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction
Global Markets Direct Report Coverage
Thymus Cancer Overview
Therapeutics Development
Pipeline Products for Thymus Cancer - Overview
Pipeline Products for Thymus Cancer - Comparative Analysis
Thymus Cancer - Therapeutics under Development by Companies
Thymus Cancer - Therapeutics under Investigation by Universities/Institutes
Thymus Cancer - Pipeline Products Glance
Clinical Stage Products
Thymus Cancer - Products under Development by Companies
Thymus Cancer - Products under Investigation by Universities/Institutes
Thymus Cancer - Companies Involved in Therapeutics Development
Merck & Co., Inc.
Nerviano Medical Sciences S.r.l.
Novartis AG
Onxeo SA
Sumitomo Dainippon Pharma Co., Ltd.
Thymus Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amrubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 1 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thymus Cancer - Recent Pipeline Updates 43
Thymus Cancer - Product Development Milestones 50
Featured News & Press Releases
Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014
May 14, 2014: Phase II data of Nerviano Medical Sciences kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO
Jul 18, 2013: Belinostat gets European orphan drug designation for the treatment of malignant thymomas
May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Thymus Cancer, H2 2014
Number of Products under Development for Thymus Cancer - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Thymus Cancer - Pipeline by Merck & Co., Inc., H2 2014
Thymus Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2014
Thymus Cancer - Pipeline by Novartis AG, H2 2014
Thymus Cancer - Pipeline by Onxeo SA, H2 2014
Thymus Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Thymus Cancer Therapeutics - Recent Pipeline Updates, H2 2014
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Visit: http://www.prnewswire.com/news/marketresearchreports.biz
Hiv disease for the last 3 years and had pain hard to eat and cough are nightmares,especially the first year At this stage, the immune system is severely weakened, and the risk of contracting opportunistic infections is much greater. However, not everyone with HIV will go on to develop AIDS. The earlier you receive treatment, the better your outcome will be.I started taking ARV to avoid early death but I had faith in God that i would be healed someday.As a Hiv patient we are advise to be taking antiretroviral treatments to reduce our chance of transmitting the virus to others , few weeks ago i came on search on the internet if i could get any information on Hiv treatment with herbal medicine, on my search i saw a testimony of someone who has been healed from Hiv her name was Achima Abelard and other Herpes Virus patient Tasha Moore also giving testimony about this same man,Called Dr Itua Herbal treatment.I was moved by the testimony and i contacted him by his Email.drituaherbalcenter@gmail.com . We chatted and he send me a bottle of herbal medicine I drank it as he instructed me to.After drinking it he ask me to go for a test that how i ended my suffering life of Hiv patent,I'm cured and free of Arv Pills.I'm forever grateful to him Doctor Itua Herbal Treatment..He assured me he can cure the following disease..Hiv,Cancer,Herpes Virus,Hpv,Pile,Weak Erection,Lyme Disease,Epilepsy,Glaucoma.,Brain Tumor,psoriasis, Cataracts,Macular degeneration,Cardiovascular disease,Chronic Diarrhea,Lung disease.Enlarged prostate,Osteoporosis.Alzheimer's disease,
ReplyDeleteDementia. ,Bladder Cancer,Autism,Colorectal Cancer,Breast Cancer,Kidney Cancer,Leukemia,Lung Cancer,Tay tach disease,Non Hodgkin Lymphoma,Skin Cancer,Lupus,Uterine Cancer,Prostate Cancer, Seizures, fibromyalgia ,ALS,Hepatitis,Copd,Parkinson disease.Genetic disease,Fibrodysplasia disease,Fibrodysplasia Ossificans Progressiva,Fluoroquinolone Toxicity Syndrome,Stroke,Hpv,Weak Erection,Liver/Kidney Inflammatory,Men/Woman infertility, bowel disease ,Huntington's disease ,Diabetes,Fibroid.